Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial
Michael Brownstein(Azevan Pharmaceuticals (United States)), Stephanie Lowenhaupt(Virginia Commonwealth University), Patricia M. Conlon(University of Pittsburgh Medical Center), Sandra K. Kostyk(Georgetown University), Jeremy M. Shefner(Barrow Neurological Institute), Lauren Seeberger(Georgetown University), Peter Hedera(Walter Reed National Military Medical Center), Jon Yankey(University of Iowa), Andrew P. Duker(University of Cincinnati), Allison M. Daley(The Ohio State University), Catherine Gladden(Massachusetts General Hospital), Eve Damiano(Azevan Pharmaceuticals (United States)), Steven M. Hersch(Eisai (United States)), Christina Gruenwald(University of Cincinnati), Neal G. Simon(Lehigh University), Jamie Adams(University of Rochester Medical Center), Angela Molloy(University of Cincinnati), Jeffrey D. Long(University of Iowa), Merit Cudkowicz(Harvard University), Matthew J. Barrett(Virginia Commonwealth University), Marianne Chase(Massachusetts General Hospital), Stewart A. Factor(Parkinson's and Movement Disorder Institute), Kelly Lowen(Vanderbilt University), Shi‐fang Lu(Lehigh University), Robin Conwit(National Institutes of Health), Amie Hiller(Oregon Health & Science University), Victor Sung(University of Alabama at Birmingham), Andrew McGarry(Cooper Medical School of Rowan University), Dixie Ecklund(University of Iowa), Valerie Suski(Georgetown University), Paul Deritis(University of Rochester Medical Center), Padraig O’Suilleabhain(Mayo Clinic), Amy M. Chesire(University of Rochester Medical Center), Melanie Benge(University of Alabama at Birmingham), Joseph F. Quinn(Oregon Health & Science University), Brenda Thornell(Massachusetts General Hospital), Debra E. Itzkowitz(Azevan Pharmaceuticals (United States)), Codrin Lungu(National Institutes of Health), Susan Perlman(University of California, Los Angeles), Karen E. Anderson(Georgetown University), Christopher S. Coffey(University of Iowa), Kellie Keith(Oregon Health & Science University), H. Diana Rosas(Massachusetts General Hospital), Frederick J. Marshall(University of Rochester Medical Center), Danny Bega(The Neurological Institute), Hilda T. Maibach(Azevan Pharmaceuticals (United States)), Michele Costigan(University of Iowa), Elaine Sperin(Emory University), Cara Jacob(University of Cincinnati), Zsazsa R. Brown(Northwestern University)
Cited by 32
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Calcium-Channel Antibodies in the Lambert–Eaton Syndrome and Other Paraneoplastic Syndromes
|New England Journal of Medicine|1995|604
Tissue-Specific Expression of a Splicing Mutation in the Gene Causes Familial Dysautonomia
|The American Journal of Human Genetics|2001|595